Brief Report

Suprascapular Nerve Block for Hemiplegic Shoulder Pain Post Stroke: Subgroup Analysis of Pain Response

Zoe Adey-Wakeling*1 (BMBS), Maria Crotty1 (PhD), Enwu Liu1 (PhD), E Michael Shanahan2 (PhD)

1Department of Rehabilitation and Aged Care, Flinders University, Australia
2Department of Rheumatology, Flinders University, South Australia, Australia

*Corresponding author: Dr. Zoe Adey-Wakeling (BMBS), Flinders University, Department of Rehabilitation and Aged Care, Repatriation General Hospital, Daws Road, Daw Park, SA Australia 5041, Tel: +61 407 374 260; Email: zoe.adey-wakeling@health.sa.gov.au

Received: 07-29-2015
Accepted: 08-19-2015
Published: 09-01-2015
Copyright: © 2015 Adey-Wakeling

Abstract

Background and Aims: Suprascapular nerve block is an effective intervention for hemiplegic shoulder pain post stroke. This study aims to ascertain baseline variables associated with significant shoulder pain reduction in a post-stroke population receiving suprascapular nerve block versus placebo.

Methods: Post hoc subgroup analysis of data from a randomised controlled trial. Participants included 64 patients with hemiplegic shoulder pain (mean onset 12 weeks post stroke); 32 received suprascapular nerve block and 32 received placebo subcutaneous normal saline injection.

Results: Greater rates of pain reduction were found in participants with severe baseline pain (p=0.0454) and participants aged under eighty (p=0.0417). Persons aged over eighty demonstrated poor response to intervention. Heterogeneity of sex interaction was associated with reduced placebo effect in females (p=0.036).

Conclusions: Participants with severe baseline pain or aged <80 years were more likely to have reduced pain following injection. Patients >80 warrant further investigations prior to consideration of this intervention. Stroke subtype and level of spasticity were not associated with response.

Keywords: Stroke; Hemiplegia; Pain; Nerve Block; Treatment; Age

Abbreviations

SSNB: Suprascapular Nerve Block;
VAS: Visual Analogue Scale;
NIHSS: National Institute of Health Stroke Scale;
MAS: Modified Ashworth Scale;

Introduction

Hemiplegic shoulder pain occurs in approximately 25-30% of the post-stroke population [1, 2], but there is a paucity of evidence-based treatments. Multiple aetiologies can contribute to the development of hemiplegic shoulder pain, including soft tissue injuries, changes in motor control, and central nervous system alterations [3]. Initial loss of motor tone can contribute to instability and subluxation, which in turn can lead to soft tissue or nerve injury [3], though there is conflicting evidence regarding the role of subluxation in the development of hemiplegic shoulder pain [4]. The impact of varying aetiologies contributes to the clinician’s dilemma in selection of appropriate, evidence-based interventions. Propylaxis includes positioning and safe manual handling techniques, though there is no causative association demonstrated [5]. Treatment options with increasing evidence base include Botulinum toxin A [6] and functional electrical stimulation [7], whilst there is conflicting evidence regarding the use of intra-articular steroid injections [7, 8].

The authors’ recent randomised controlled study [9] demonstrated statistically and clinically significant benefits of suprascapular nerve block (SSNB) in a post-stroke population. This safe and effective treatment [10] warrants further studies in larger populations to provide greater understanding of characteristics of clinical responders and the impact of effective pain management on independence and quality of life.

Whilst larger scale studies are awaited, it is clinically relevant to consider which patients are the best candidates for the intervention. Reviewing the original trial data, this paper aims to explore the clinical variables associated with greatest reduction in reported pain.

Methods

A ‘within study’ post hoc subgroup analysis was performed on the data from Suprascapular nerve block for shoulder pain in the first year after stroke: a randomised controlled trial (AC-TRN12609000621213) [9]. This randomised controlled trial assessed the effectiveness of SSNB on primary outcome of pain (100mm visual analogue scale, VAS) in a population of 64 stroke survivors with hemiplegic shoulder pain >30mm. The original paper [9, 11] outlines the ethics approval, informed consent, full methodology and outcomes. Patients were randomised to receive intervention (SSNB) or placebo injection. Suprascapular nerve block (10ml 0.5% bupivacaine hydrochloride and 1mL of 40mg/mL methylprednisolone) was performed via posterior approach, with use of anatomical landmarks to inject into the supraspinous fossa [12]. The placebo group received 5mL normal saline subcutaneous injection to the same region of the shoulder. Baseline demographics showed that the intervention group (n=32) consisted of 65.6% males, whilst the placebo group (n=32) was 46.9% males. The majority of participants suffered ischaemic stroke (84.4% in intervention group, 90.6% in control group). There was a greater proportion of elderly participants in the intervention group (25% aged 80 years and over) versus placebo (9.4% aged over 80). Patients were assessed at baseline, and followed up at one week, one month and three months. The intervention group demonstrated a statistically and clinically significant pain reduction when compared to control.

Subgroup analyses were performed to assess the interaction of treatment allocation with seven key baseline variables including age, gender, stroke subtype (ischaemic vs haemorrhagic), upper limb motor deficit on National Institute of Health Stroke Scale (NIHSS) upper limb motor subscale, pain type (movement vs rest / night), spasticity, and VAS. Continuous baseline variables were dichotomised into clinically relevant binary outcomes for the analyses: NIHSS upper limb score definitions were split into ‘able to maintain antigravity’ (0-2) vs ‘unable to maintain antigravity’ (3+); severe pain was defined as VAS ≥75mm and mild-moderate pain as <75mm [13]; spasticity (Modified Ashworth Scale, MAS) was dichotomised as ‘none’ (MAS 0) or ‘any’ (MAS 1+).

Subgroup analyses were conducted by incorporating interaction terms into linear mixed models. The overall treatment effect for the subgroup were calculated by lsmens statement with a 2-way interaction term subgroup*treatment with cl and diff option by SAS linear mixed models. Means, mean difference, confidence intervals and p values at different time points were calculated by lsmens statement with a 3-way interaction term subgroup*treatment*time with cl and diff option by SAS linear mixed models. All p values were two sided. Analyses were performed in SAS 9.3 (SAS Institute, Cary NC).

Results

Age under 80 and higher baseline pain scores are associated with more significant response to suprascapular nerve block intervention in hemiplegic shoulder pain. No significant interactions were found between treatment group and stroke type (ischaemic vs haemorrhagic), or baseline level of spasticity, pain type, or upper limb motor deficit, illustrating that treatment effect was not likely to be influenced by these factors. Subgroup analysis (Figures 1 and 2) suggest overall heterogeneity of treatment interactions for sex (p=0.036), age (p=0.0417) and severity of baseline pain (p=0.0454), indicative of impact on response to intervention. Figure 2 outlines p values for separated time points. P values reported test the hypothesis that mean differences (control-intervention) are zero.

Whilst participants aged under 80 had significant response to intervention, those aged over 80 demonstrated poor response. The interaction between treatment and sex appears related to the reduced impact of placebo on females (Figure 1), with equivalent effect of active intervention in both males and females.
Figure 1. Subgroup analysis - treatment and time effects.

VAS Visual Analogue Scale

There have been no previous published placebo-controlled randomised controlled trials of SSNB in a stroke population. As such, this subgroup analysis provides a first suggestion of participant variables which may increase the likelihood of a positive response. Similar analyses in non-stroke populations were not found, but subgroup analyses on stroke patients with hemiplegic shoulder pain have been reported in the context of

<table>
<thead>
<tr>
<th>Subgroups</th>
<th>Mean difference [95% CI]</th>
<th>P values</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Male</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>baseline</td>
<td>-1.4 [-17.3, 14.5]</td>
<td>0.8621</td>
</tr>
<tr>
<td>week4</td>
<td>12.1 [-4.85, 29.0]</td>
<td>0.1603</td>
</tr>
<tr>
<td>week12</td>
<td>-4.5 [-22.2, 13.1]</td>
<td>0.6100</td>
</tr>
<tr>
<td>overall</td>
<td>2.0 [-9.8, 13.9]</td>
<td>0.7296</td>
</tr>
<tr>
<td><strong>Female</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>baseline</td>
<td>6.5 [-11.8, 24.9]</td>
<td>0.4834</td>
</tr>
<tr>
<td>week4</td>
<td>23.2 [4.6, 41.7]</td>
<td>0.0150</td>
</tr>
<tr>
<td>week12</td>
<td>33.8 [15.4, 52.2]</td>
<td>0.0004</td>
</tr>
<tr>
<td>overall</td>
<td>21.2 [8.0, 34.3]</td>
<td>0.0021</td>
</tr>
<tr>
<td><strong>39-79 year</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>baseline</td>
<td>1.4 [-11.6, 14.4]</td>
<td>0.8303</td>
</tr>
<tr>
<td>week4</td>
<td>24.1 [10.7, 37.5]</td>
<td>0.0005</td>
</tr>
<tr>
<td>week12</td>
<td>24.4 [10.9, 38.0]</td>
<td>0.0005</td>
</tr>
<tr>
<td>overall</td>
<td>16.6 [7.4, 25.9]</td>
<td>0.0007</td>
</tr>
<tr>
<td><strong>80+ year</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>baseline</td>
<td>4.2 [-24.3, 32.8]</td>
<td>0.7691</td>
</tr>
<tr>
<td>week4</td>
<td>-10.6 [-39.2, 19.9]</td>
<td>0.4625</td>
</tr>
<tr>
<td>week12</td>
<td>-15.1 [-43.7, 13.4]</td>
<td>0.2963</td>
</tr>
<tr>
<td>overall</td>
<td>-7.2 [-27.2, 12.8]</td>
<td>0.4753</td>
</tr>
<tr>
<td><strong>Mild to moderate pain</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>baseline</td>
<td>1.2 [-14.2, 16.5]</td>
<td>0.8834</td>
</tr>
<tr>
<td>week4</td>
<td>3.8 [-11.8, 19.4]</td>
<td>0.6311</td>
</tr>
<tr>
<td>week12</td>
<td>5.9 [-10.1, 21.8]</td>
<td>0.4658</td>
</tr>
<tr>
<td>overall</td>
<td>3.6 [-7.5, 14.7]</td>
<td>0.5190</td>
</tr>
<tr>
<td><strong>Severe pain</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>baseline</td>
<td>1.6 [-15.3, 18.5]</td>
<td>0.8541</td>
</tr>
<tr>
<td>week4</td>
<td>31.0 [13.3, 48.8]</td>
<td>0.0008</td>
</tr>
<tr>
<td>week12</td>
<td>28.7 [11.0, 46.5]</td>
<td>0.0042</td>
</tr>
<tr>
<td>overall</td>
<td>20.4 [8.1, 32.8]</td>
<td>0.0016</td>
</tr>
</tbody>
</table>

Figure 2. Subgroup analysis treatment effects.

**Discussion**

The author’s randomised controlled trial concluded that SSNB is an effective intervention for hemiplegic shoulder pain. Subgroup analyses suggest that this intervention is most effective in patients aged <80 or with severe baseline pain.

findings suggest its effects are not confined to one stroke sub-
treated injection. The authors [14] report-
ed that subgroup analyses supported the hypothesis that pa-
tients with neglect, visual field deficit and sensory deficits had
higher risk of shoulder injury and subsequent capsulitis, and
thus less likely to respond to intra-articular injection. Compar-
ison to this study is not possible, as SSNB is effective in ad-
hesive capsulitis [15] and the studies do not use comparable
exclusion criteria or outcome measures.

It is important to consider these findings in context of clinical
plausibility. Subgroup variables were selected within a clinical
framework where interactions were conceivable. Statistically
significant interactions were suggested for females, those aged
<80, and patients with severe baseline pain. Whilst there is
evidence suggesting sex differences in pain experience and an-
algic response [16], the finding in the current paper reflects
reduced placebo response in females (Figure 1). Previous
research has observed reduced placebo responses in females
[17,18], with hypothesised explanations including biochemical
differences and absence of stress relief in females receiving
placebo. Whilst this sex difference is biologically plausible in
a placebo controlled trial, this finding should not influence the
decision for administration of an active intervention. Age >80
was associated with poor intervention response, whilst partic-
ips aged <80 demonstrated increased likelihood of favour-
able response. Additional underlying pathologies may affect
response in older people, and shoulder imaging may play a
more important role in guiding treatment in a more complex
presentation of hemiplegic shoulder pain. Greater response in
those with severe baseline pain is consistent with previously
documented effectiveness of SSNB in severe pain [19], and
supports the role of this intervention in cases non-responsive
to simple analgesics and conservative therapies.

Not all subgroups analysed demonstrated significant interac-
tions, including spasticity and degree of motor deficit. P values
on separated analyses of spasticity data indicated interaction,
but overall interaction analysis suggest lack of heterogeneity of
treatment effect. It has been postulated that patients with
significant spasticity may achieve optimal response if the spas-
ticity is treated [20] but we were unable to find any sugges-
tion that the level of spasticity was associated with pain or re-
sponse to treatment.

Findings of subgroup analyses are observational and have in-
herent limitations. The post hoc nature of our analyses im-
acts on the reliability of results. This is a small trial and we
performed only seven ‘within study’ analyses.

Summary and Conclusion

Shoulder pain following stroke is a common problem with lim-
ited treatment options. SSNB is a promising treatment and our
findings suggest its effects are not confined to one stroke sub-
type. Greatest response occurs in patients aged <80 and those
with high reported baseline pain. Whilst no definitive conclu-
sions should be drawn from this analysis, the results generate
interesting hypotheses for consideration in larger powered
future studies.

Acknowledgements

The randomised controlled trial was supported by a grant
from Foundation Daw Park, Repatriation General Hospital.

References

1. Lindgren I, Jonsson A, Norving B, Lindgren A. Shoulder pain
after stroke: A prospective population -Based study. Stroke.
2. Adey-Wakeling ZAH, Crotty M, Leyden J, Kleinig T, Anderson
CS, Newbury J. Incidence and associations of hemiplegic shoul-
der pain post stroke: A prospective population based study.
3. Kalichman L, Ratmansky M. Underlying pathology and as-
related features of hemiplegic shoulder pain.. Am J Phys Med
Rehab. 2011, ; 90(9): 768-780.
4. Teasell R, Foley N, Bhogal S. Evidence-based review of stroke
rehabilitation: Painful hemiplegic shoulder. Evidence based re-
view of stroke rehabilitation. 2006; 2009.
5. Maxwell AMW NV. Management of the hemiplegic shoulder.
Cochrane Database Syst Rev. 2010, 8(9); CD008271
7. Koog YH, Jin SS, Yoon K, Min BI. Interventions for hemiplegic
shoulder pain: systematic review of randomised controlled tri-
als. Disabil Rehabil. 2010, 32(4); 282-291.
8. Lakse E, GunduzB, Erhan B, Celik EC. The effect of local injec-
tions in hemiplegic shoulder pain: A prospective, randomised,
controlled study. Am J Phys Med Rehabil. 2009, 88(10); 805-
811.
nerve block for shoulder pain in the first year after stroke: A
Safety and acceptability of suprascapular nerve block in rheu-
11. Allen ZA, Shanahan EM, Crotty M. Does suprascapular
nerve block reduce shoulder pain after stroke: A double-blind


13. Hawker GA, Mian S, Kendzerska T, French M. Measures of adult pain: Visual Analog Scale for Pain (VAS Pain), Numeric Rating Scale for Pain (NRS Pain), McGill Pain Questionnaire (MPQ), Short-Form McGill Pain Questionnaire (SF-MPQ), Chronic Pain Grade Scale (CPGS), Short Form-36 Bodily Pain Scale (SF-36 BPS), and Measure of Intermittent and Constant Osteoarthritis Pain (ICOAP). J Rheumatol. 2011, 63 suppl 11: S240-S252.


